BioCentury
ARTICLE | Clinical News

SNS01-T: Additional Phase Ib/IIa data

September 24, 2012 7:00 AM UTC

Interim data from 3 evaluable patients in the first cohort of an open-label, dose-escalation, U.S. Phase Ib/IIa trial showed that 0.0125 mg/kg SNS01-T led to 2 cases of stable disease, including 1 pat...